{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-018333","form_type":"8-K","ticker":"PRPH","cik":"0000868278","company_name":"ProPhase Labs, Inc.","filed_at":"2024-05-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:22.220755+00:00","generated_at":"2026-06-02T07:56:16.197264+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ProPhase Labs Q1 net loss $6.3M; revenue drops to $3.6M; explores sale of Pharmaloz","bullets":["Net loss of $6.3M ($0.07 loss per share) vs net income of $0.6M ($0.03 EPS) in Q1 2023.","Revenue declined 81% to $3.6M from $19.3M, driven by zero COVID-19 testing vs 120K tests year ago.","Pharmaloz Manufacturing exploring strategic alternatives including potential sale; signed two deals worth >$5M annual additional revenue.","BE-Smart esophageal cancer test on track for H2 2024 commercialization; Project ZenQ-AI launched using AI for cancer therapy.","Cash at April 30: $4.6M; raised $2.5M via receivables securitization and $3.6M from partial investment sale."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-018333","json":"https://secwatch.observer/filing/0001493152-24-018333.json","markdown":"https://secwatch.observer/filing/0001493152-24-018333.md","text":"https://secwatch.observer/filing/0001493152-24-018333.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/868278/000149315224018333/0001493152-24-018333-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/868278/000149315224018333/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-02T07:56:16.197264+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"dc8b0a66b838681cdee3427b3332e74aeba2055b","claim":"ProPhase Labs, Inc. reported financial results for first quarter ended March 31, 2024.","evidence_excerpt":"On May 9, 2024, ProPhase Labs, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/868278/000149315224018333/0001493152-24-018333-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2024"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}